Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir.
about
Genome-wide association study identifies single nucleotide polymorphism in DYRK1A associated with replication of HIV-1 in monocyte-derived macrophagesNeurologic complications of HIV-1 infection and its treatment in the era of antiretroviral therapyMechanistic insights on immunosenescence and chronic immune activation in HIV-tuberculosis co-infectionModeling of HIV-1 infection: insights to the role of monocytes/macrophages, latently infected T4 cells, and HAART regimesThe HIV-1 Vpu viroporin inhibitor BIT225 does not affect Vpu-mediated tetherin antagonismAntiviral efficacy of the novel compound BIT225 against HIV-1 release from human macrophages.NFAT5 regulates HIV-1 in primary monocytes via a highly conserved long terminal repeat sitePhosphatidylcholine-specific phospholipase C activation is required for CCR5-dependent, NF-kB-driven CCL2 secretion elicited in response to HIV-1 gp120 in human primary macrophages.The SET complex acts as a barrier to autointegration of HIV-1GTP activator and dNTP substrates of HIV-1 restriction factor SAMHD1 generate a long-lived activated stateMolecular mechanisms of HIV-1 persistence in the monocyte-macrophage lineageThe contribution of peroxynitrite generation in HIV replication in human primary macrophages.HIV-1 Nef induces proinflammatory state in macrophages through its acidic cluster domain: involvement of TNF alpha receptor associated factor 2.Impact of short-term combined antiretroviral therapy on brain virus burden in simian immunodeficiency virus-infected and CD8+ lymphocyte-depleted rhesus macaques.Restriction of HIV-1 replication in macrophages and CD4+ T cells from HIV controllers.Antiretroviral therapy in macrophages: implication for HIV eradication.Antiviral effects of human immunodeficiency virus type 1-specific small interfering RNAs against targets conserved in select neurotropic viral strains.Toll-like receptor 3 signaling inhibits simian immunodeficiency virus replication in macrophages from rhesus macaquesHIV DNA is heavily uracilated, which protects it from autointegrationControversies in HIV-associated neurocognitive disordersTenofovir: a nucleotide analog for the management of human immunodeficiency virus infection.Giant cell encephalitis and microglial infection with mucosally transmitted simian-human immunodeficiency virus SHIVSF162P3N in rhesus macaquesSustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages.Compartmentalization of human immunodeficiency virus type 1 between blood monocytes and CD4+ T cells during infection.The next generation of HIV/AIDS drugs: novel and developmental antiHIV drugs and targets.Critical role for antiapoptotic Bcl-xL and Mcl-1 in human macrophage survival and cellular IAP1/2 (cIAP1/2) in resistance to HIV-Vpr-induced apoptosis.Human immunodeficiency virus (HIV) latency: the major hurdle in HIV eradicationHIV-1 infection induces changes in expression of cellular splicing factors that regulate alternative viral splicing and virus production in macrophages.HIV-1 Nef in macrophage-mediated disease pathogenesis.Nanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites.Uracil DNA glycosylase initiates degradation of HIV-1 cDNA containing misincorporated dUTP and prevents viral integration.Cell-cell contact viral transfer contributes to HIV infection and persistence in astrocytesMonocyte/macrophages and their role in HIV neuropathogenesis.Vaginal microbicides and the prevention of HIV transmissionEffects of vaccinia virus uracil DNA glycosylase catalytic site and deoxyuridine triphosphatase deletion mutations individually and together on replication in active and quiescent cells and pathogenesis in mice.Uracil within DNA: an actor of antiviral immunity.Peritoneal macrophage uptake, pharmacokinetics and biodistribution of macrophage-targeted PEG-fMLF (N-formyl-methionyl-leucyl-phenylalanine) nanocarriers for improving HIV drug delivery.Update on HIV-associated neurocognitive disorders.Enfuvirtide cerebrospinal fluid (CSF) pharmacokinetics and potential use in defining CSF HIV-1 originOptimizing size and copy number for PEG-fMLF (N-formyl-methionyl-leucyl-phenylalanine) nanocarrier uptake by macrophages.
P2860
Q21135536-BA4C217F-B951-48E0-8AEB-A267334D285DQ27000422-23493D6B-4E40-4DE2-A99F-B9A238C00C9EQ28081838-31806952-96E8-492C-BF9E-454CC2F50049Q28484046-F3CD98C7-0DDD-4A11-A673-1E4BE6BBDEB2Q28742774-766C6D80-A566-4D9D-A8F1-06C7397B89B1Q30968332-C0A54718-58B9-4813-AE92-9C50162C77B6Q33266806-69B4F09B-43DC-4FD4-9AAC-AE6A3C1C2F07Q33315307-64B287B1-2EDC-4F27-82DD-4552069ADB53Q33415459-F624550F-3617-482F-8755-4DDF95BD95F8Q33606917-0A7D8ABA-EDE7-4946-9C71-03A964C98021Q33864438-011680D4-7118-4452-95AD-411D5BDBCF24Q34007680-83D519E3-7291-4275-AFD7-B01A23AC0B34Q34008771-EDA9522B-3D0D-4959-8897-CC91063412E6Q34033558-2EB5D22A-53FB-41C0-93DC-A6F37948AB50Q34189960-D652C4A7-0069-4C07-87E7-52119A4F6B18Q34298792-2DCDB66D-25DA-470D-A986-6CA6811217FBQ34371320-EF7F6F42-217E-40BE-8985-1B4D7528B93FQ34646625-7C89FAC1-AB06-4EEB-9D85-7E5CE9E918DAQ35022023-4C5DD63A-E64D-4897-9BA6-964051D750A1Q35037015-950FB80D-1749-4ECC-A6EF-9DBF3055B8E2Q35043368-0BE9C0AB-F6F1-4D2E-BA03-DE013B8136F4Q35110503-C3DE62A4-A5F5-40BD-880B-254B51C93830Q35149275-D3137C2F-976E-4C6D-805A-B2930E847ED3Q35704022-0D94A924-617D-44CC-8D7F-102B2A6BE56DQ35917148-829C77C2-826C-4C8A-8A57-3416855738A1Q35922613-91313809-BA1B-4301-8976-F303BDA95ABDQ36330062-98DE6052-DEA5-4F00-BC0A-BEF8D42F3000Q36496484-27C5A6E0-783A-485A-A926-892603A13170Q36531107-F05DC462-2125-41C8-B15D-8CE2D42955D3Q36583732-C336903B-B3FB-494B-8498-7DC78D9BA2E8Q36598240-41235802-AEDF-46A7-9428-9F332EB1697BQ36883462-92AE8C3A-6687-4AD9-9CDD-237782B96658Q36991666-AC9CC812-E002-4658-AD1B-96B794C8A2E5Q37063819-1D2A5EAB-2EC3-4BB0-8FC4-ECD87703E126Q37072891-2668F4FD-3D86-4650-9CC2-6D89678A0878Q37183492-91D9887B-506B-42B2-87BD-C2E36C72DEA2Q37192494-DBC50D3C-0AC2-4F28-BF31-A0C1429E0C41Q37200962-75D98590-AAC6-426C-B7D3-A8D5639257D5Q37235279-7668B194-27FD-4AB8-BF7F-BA5C3F34CE5BQ37310990-5AD1804D-C4FA-4369-9A3C-FED1A544D927
P2860
Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir.
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Macrophages and HIV infection: ...... his strategic virus reservoir.
@ast
Macrophages and HIV infection: ...... his strategic virus reservoir.
@en
Macrophages and HIV infection: ...... his strategic virus reservoir.
@nl
type
label
Macrophages and HIV infection: ...... his strategic virus reservoir.
@ast
Macrophages and HIV infection: ...... his strategic virus reservoir.
@en
Macrophages and HIV infection: ...... his strategic virus reservoir.
@nl
prefLabel
Macrophages and HIV infection: ...... his strategic virus reservoir.
@ast
Macrophages and HIV infection: ...... his strategic virus reservoir.
@en
Macrophages and HIV infection: ...... his strategic virus reservoir.
@nl
P2093
P1433
P1476
Macrophages and HIV infection: ...... his strategic virus reservoir.
@en
P2093
Enrico Garaci
Maria Concetta Bellocchi
Raffaele Caliò
Stefano Aquaro
P304
P356
10.1016/S0166-3542(02)00052-9
P577
2002-08-01T00:00:00Z